Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

749 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
CB1 antagonists for obesity--what lessons have we learned from rimonabant?
Di Marzo V, Després JP. Di Marzo V, et al. Among authors: despres jp. Nat Rev Endocrinol. 2009 Nov;5(11):633-8. doi: 10.1038/nrendo.2009.197. Nat Rev Endocrinol. 2009. PMID: 19844251
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group. Després JP, et al. N Engl J Med. 2005 Nov 17;353(20):2121-34. doi: 10.1056/NEJMoa044537. N Engl J Med. 2005. PMID: 16291982 Clinical Trial.
[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
Scheen AJ, Van Gaal LG, Després JP, Pi-Sunyer X, Golay A, Hanotin C. Scheen AJ, et al. Among authors: despres jp. Rev Med Suisse. 2006 Aug 23;2(76):1916-23. Rev Med Suisse. 2006. PMID: 16972542 Review. French.
Abdominal obesity and metabolic syndrome.
Després JP, Lemieux I. Després JP, et al. Nature. 2006 Dec 14;444(7121):881-7. doi: 10.1038/nature05488. Nature. 2006. PMID: 17167477 Review.
Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.
Ruilope LM, Després JP, Scheen A, Pi-Sunyer X, Mancia G, Zanchetti A, Van Gaal L. Ruilope LM, et al. Among authors: despres jp. J Hypertens. 2008 Feb;26(2):357-67. doi: 10.1097/HJH.0b013e3282f2d625. J Hypertens. 2008. PMID: 18192851 Clinical Trial.
Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A. Van Gaal L, et al. Among authors: despres jp. Diabetes Care. 2008 Feb;31 Suppl 2:S229-40. doi: 10.2337/dc08-s258. Diabetes Care. 2008. PMID: 18227491
Efficacy and safety of the weight-loss drug rimonabant.
Després JP, Van Gaal L, Pi-Sunyer X, Scheen A. Després JP, et al. Lancet. 2008 Feb 16;371(9612):555; author reply 556-7. doi: 10.1016/S0140-6736(08)60261-5. Lancet. 2008. PMID: 18280320 No abstract available.
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM; STRADIVARIUS Investigators. Nissen SE, et al. Among authors: despres jp. JAMA. 2008 Apr 2;299(13):1547-60. doi: 10.1001/jama.299.13.1547. Epub 2008 Apr 1. JAMA. 2008. PMID: 18387931 Clinical Trial.
Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
Després JP, Ross R, Boka G, Alméras N, Lemieux I; ADAGIO-Lipids Investigators. Després JP, et al. Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):416-23. doi: 10.1161/ATVBAHA.108.176362. Epub 2008 Dec 26. Arterioscler Thromb Vasc Biol. 2009. PMID: 19112166 Clinical Trial.
Pleiotropic effects of rimonabant: clinical implications.
Després JP. Després JP. Curr Pharm Des. 2009;15(5):553-70. doi: 10.2174/138161209787315666. Curr Pharm Des. 2009. PMID: 19199981 Review.
749 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback